YRDC is a Prognostic-Related Biomarker Correlated With Immune Infiltration and Drug Sensitivity in Pan-Cancer

Background

YRDC has emerged as a potential biomarker in cancer, yet its prognostic value, oncogenic mechanisms, role in immune infiltration, and anticancer drugs efficacy in pan-cancer remained poorly understood.

Aims

This study aimed to comprehensively investigate YRDC's role in pan-cancer and to explore the potential effects of YRDC on the immune infiltration pattern and anticancer drug sensitivity.

Methods and Results

Based on bioinformatics analysis of multi-omics data, we firstly demonstrated that YRDC was markedly overexpressed and associated with worse prognosis in various tumors. Further, our results indicated that genetic alterations, copy number variations, and methylation levels of YRDC might explain the different YRDC expression between tumors and controls. Additionally, YRDC might promote cancer via enhancing tumor cell proliferation, modulating immune cell infiltration, and enhancing drug resistance. Notably, YRDC emerged as a potential biomarker for predicting immunotherapy response and targeted drug efficacy.

Conclusion

Our study identifies YRDC as a novel therapeutic target and a promising biomarker for cancer progression, immunotherapy response, and targeted drug sensitivity across pan-cancers. These findings provide evidence for further research into YRDC's role in cancer biology and future clinical exercises.